30 years of historical data (1996–2025) · Healthcare · Medical - Care Facilities
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
U.S. Physical Therapy, Inc. trades at 44.6x earnings, roughly in line with its 5-year average of 44.3x, sitting at the 73rd percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 102%. On a free-cash-flow basis, the stock trades at 15.8x P/FCF, 18% below the 5-year average of 19.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $964M | $1.2B | $1.3B | $1.3B | $1.1B | $1.2B | $1.5B | $1.5B | $1.3B | $908M | $878M |
| Enterprise Value | $1.4B | $1.6B | $1.6B | $1.4B | $1.3B | $1.4B | $1.6B | $1.6B | $1.3B | $946M | $909M |
| P/E Ratio → | 44.59 | 54.99 | 48.21 | 72.77 | 24.26 | 21.28 | 29.40 | 25.47 | 127.94 | 41.02 | 42.80 |
| P/S Ratio | 1.23 | 1.52 | 1.99 | 2.18 | 1.90 | 2.49 | 3.65 | 3.03 | 2.86 | 2.19 | 2.46 |
| P/B Ratio | 1.25 | 1.54 | 1.76 | 2.03 | 2.17 | 2.72 | 3.76 | 3.84 | 3.70 | 2.94 | 3.40 |
| P/FCF | 15.81 | 19.43 | 20.32 | 18.18 | 20.92 | 18.07 | 16.71 | 27.91 | 19.70 | 18.36 | 20.51 |
| P/OCF | 12.85 | 15.79 | 17.83 | 16.12 | 17.97 | 16.13 | 15.43 | 23.36 | 17.76 | 16.06 | 17.19 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
U.S. Physical Therapy, Inc.'s enterprise value stands at 13.2x EBITDA, 28% below its 5-year average of 18.3x. The Healthcare sector median is 14.2x, placing the stock at a 7% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.02 | 2.37 | 2.36 | 2.38 | 2.88 | 3.83 | 3.26 | 2.89 | 2.29 | 2.55 |
| EV / EBITDA | 13.17 | 15.32 | 19.42 | 21.06 | 18.39 | 17.35 | 25.76 | 20.29 | 18.74 | 14.69 | 15.59 |
| EV / EBIT | 16.84 | 18.05 | 23.31 | 24.32 | 21.45 | 19.25 | 24.15 | 21.55 | 21.09 | 17.26 | 18.32 |
| EV / FCF | — | 25.83 | 24.18 | 19.64 | 26.17 | 20.92 | 17.56 | 30.10 | 19.95 | 19.15 | 21.25 |
Margins and return-on-capital ratios measuring operating efficiency
U.S. Physical Therapy, Inc. earns an operating margin of 10.3%. Operating margins have expanded from 8.6% to 10.3% over the past 3 years, signaling improving operational efficiency. ROE of 2.0% is modest. ROIC of 5.6% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 20.1% | 20.1% | 18.5% | 20.1% | 20.3% | 23.7% | 22.3% | 23.3% | 22.4% | 21.9% | 23.0% |
| Operating Margin | 10.3% | 10.3% | 9.4% | 8.6% | 10.3% | 14.3% | 12.4% | 14.0% | 13.3% | 13.2% | 13.9% |
| Net Profit Margin | 1.9% | 1.9% | 3.9% | 2.4% | 5.1% | 5.6% | 7.2% | 5.8% | 2.2% | 5.4% | 5.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.0% | 2.0% | 3.7% | 2.6% | 6.0% | 6.5% | 7.7% | 7.7% | 3.1% | 7.9% | 8.9% |
| ROA | 1.3% | 1.3% | 2.4% | 1.6% | 3.5% | 4.1% | 5.3% | 5.6% | 2.3% | 5.8% | 6.5% |
| ROIC | 5.6% | 5.6% | 5.4% | 5.2% | 6.1% | 9.3% | 8.0% | 11.7% | 12.7% | 12.9% | 14.2% |
| ROCE | 7.6% | 7.6% | 6.5% | 6.2% | 7.9% | 12.1% | 10.5% | 15.0% | 15.5% | 15.5% | 16.9% |
Solvency and debt-coverage ratios — lower is generally safer
U.S. Physical Therapy, Inc. carries a Debt/EBITDA ratio of 4.1x, which is highly leveraged (29% above the sector average of 3.2x). Net debt stands at $390M ($426M total debt minus $36M cash). Interest coverage of 9.2x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.55 | 0.55 | 0.39 | 0.40 | 0.61 | 0.49 | 0.27 | 0.36 | 0.11 | 0.20 | 0.20 |
| Debt / EBITDA | 4.14 | 4.14 | 3.61 | 3.82 | 4.13 | 2.71 | 1.76 | 1.78 | 0.57 | 0.94 | 0.89 |
| Net Debt / Equity | — | 0.51 | 0.33 | 0.16 | 0.54 | 0.43 | 0.19 | 0.30 | 0.05 | 0.13 | 0.12 |
| Net Debt / EBITDA | 3.79 | 3.79 | 3.10 | 1.56 | 3.69 | 2.37 | 1.24 | 1.47 | 0.24 | 0.60 | 0.54 |
| Debt / FCF | — | 6.40 | 3.86 | 1.46 | 5.24 | 2.85 | 0.85 | 2.19 | 0.25 | 0.79 | 0.74 |
| Interest Coverage | 9.23 | 9.23 | 8.51 | 6.31 | 10.62 | 78.70 | 41.09 | 35.11 | 30.49 | 2.60 | 4.32 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.01x means U.S. Physical Therapy, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.28x to 1.01x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.01 | 1.01 | 1.18 | 2.28 | 1.30 | 1.14 | 0.94 | 1.41 | 1.89 | 1.95 | 2.68 |
| Quick Ratio | 1.01 | 1.01 | 1.18 | 2.28 | 1.30 | 1.14 | 0.94 | 1.41 | 1.89 | 1.95 | 2.68 |
| Cash Ratio | 0.26 | 0.26 | 0.36 | 1.50 | 0.37 | 0.34 | 0.35 | 0.39 | 0.56 | 0.55 | 0.81 |
| Asset Turnover | — | 0.65 | 0.58 | 0.61 | 0.64 | 0.66 | 0.71 | 0.86 | 1.02 | 0.99 | 1.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 30.03 | 46.58 | 31.30 | 45.27 | 46.02 | 43.96 | 42.45 | 41.41 | 44.40 | 42.47 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
U.S. Physical Therapy, Inc. returns 3.4% to shareholders annually — split between a 2.8% dividend yield and 0.6% buyback yield. The payout ratio exceeds 100% at 181.7%, meaning the company is paying out more than it earns — this level is unsustainable long-term without earnings recovery. The earnings yield of 2.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.8% | 2.3% | 2.0% | 1.8% | 2.0% | 1.5% | 0.3% | 1.0% | 0.9% | 1.1% | 1.0% |
| Payout Ratio | 181.7% | 181.7% | 100.3% | 164.4% | 75.4% | 67.5% | 13.4% | 51.7% | 115.5% | 45.2% | 41.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.2% | 1.8% | 2.1% | 1.4% | 4.1% | 4.7% | 3.4% | 3.9% | 0.8% | 2.4% | 2.3% |
| FCF Yield | 6.3% | 5.1% | 4.9% | 5.5% | 4.8% | 5.5% | 6.0% | 3.6% | 5.1% | 5.4% | 4.9% |
| Buyback Yield | 0.6% | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 3.4% | 2.8% | 2.0% | 1.8% | 2.0% | 1.5% | 0.3% | 1.0% | 0.9% | 1.1% | 1.0% |
| Shares Outstanding | — | $15M | $15M | $14M | $13M | $13M | $13M | $13M | $13M | $13M | $13M |
Compare USPH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $964M | 44.6 | 13.2 | 15.8 | 20.1% | 10.3% | 2.0% | 5.6% | 4.1 | |
| $77M | -3.4 | — | 6.8 | 90.7% | -43.6% | -11.0% | -4.1% | — | |
| $426M | -4.5 | 24.0 | 10.6 | 18.7% | -0.3% | -25.6% | -0.9% | 0.2 | |
| $3B | 26.3 | 16.6 | 21.2 | 67.8% | 9.5% | 11.7% | 9.9% | 0.5 | |
| $9B | 26.3 | 23.5 | 24.2 | 13.7% | 8.6% | 16.9% | 7.0% | 7.7 | |
| $2B | -2.0 | 8.3 | — | 17.6% | 11.7% | -41.4% | 5.9% | 4.6 | |
| $2B | 14.0 | 12.1 | 5.4 | 11.5% | 6.1% | 7.3% | 4.8% | 7.8 | |
| $2B | -23.9 | 10.1 | 9.7 | 23.1% | 11.8% | -2.2% | 4.1% | 7.1 | |
| $3B | 17.3 | 7.9 | 13.3 | 18.1% | 6.0% | 15.2% | 15.3% | — | |
| $2B | 18.1 | 12.2 | 16.9 | 32.5% | 9.7% | 9.3% | 8.8% | 1.3 | |
| $8B | 69.5 | 55.1 | 105.3 | 73.8% | 4.5% | 25.2% | 8.6% | 7.9 | |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying USPH stock.
U.S. Physical Therapy, Inc.'s current P/E ratio is 44.6x. The historical average is 36.8x. This places it at the 73th percentile of its historical range.
U.S. Physical Therapy, Inc.'s current EV/EBITDA is 13.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 11.2x.
U.S. Physical Therapy, Inc.'s return on equity (ROE) is 2.0%. The historical average is 13.2%.
Based on historical data, U.S. Physical Therapy, Inc. is trading at a P/E of 44.6x. This is at the 73th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
U.S. Physical Therapy, Inc.'s current dividend yield is 2.85% with a payout ratio of 181.7%.
U.S. Physical Therapy, Inc. has 20.1% gross margin and 10.3% operating margin. Operating margin between 10-20% is typical for established companies.
U.S. Physical Therapy, Inc.'s Debt/EBITDA ratio is 4.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.